Prof. Dr. med. Arndt Hartmann

Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial (2019) Diefenhardt M, Hofheinz RD, Martin D, Beißbarth T, Arnold D, Hartmann A, von der Grün J, et al. Journal article Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab (2019) Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiss CA, Wirtz RM, Wach S, et al. Journal article FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer (2019) Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R, Eckstein M, et al. Journal article BRAF mutation testing in melanoma: results from a German observational multicenter study (2019) Hartmann A, Schirmacher P, Sterlacci W, Koch W, Liesenfeld DB, Schif B, Garbe C Journal article Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options (2019) Ahrens M, Scheich S, Hartmann A, Bergmann L Journal article, Review article Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis (2019) Fasching P, Hartkopf AD, Gaß P, Häberle L, Akpolat-Basci L, Hein A, Volz B, et al. Journal article High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma (2019) Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stoeckle M, Becker F, et al. Journal article Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands (2019) Haller F, Bieg M, Will R, Koerner C, Weichenhan D, Bott A, Ishaque N, et al. Journal article MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies (2018) Galon J, Mlecnik B, Hermitte F, Marliot F, Bifulco C, Lugli A, Nagtegaal ID, et al. Conference contribution Immunoscore feasibility study in routine postsurgical pathologic review for early-stage colon cancer (CC) cases risk-assessment (2018) Belaloui K, Malifarge E, Bohm J, Bossard C, Dienstmann R, Garcia S, Geppert CI, et al. Conference contribution